Trials / Completed

CompletedNCT00002080

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: —

Sponsor: Pharmacia · Industry
Sex: All
Age: 12 Years
Healthy volunteers: Not accepted

Summary

Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin. Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts = or \< 200.

Conditions

Mycobacterium Avium-intracellulare Infection
HIV Infections

Interventions

Type	Name	Description
DRUG	Rifabutin

Timeline

First posted: 2001-08-31
Last updated: 2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00002080. Inclusion in this directory is not an endorsement.